Lamivudine treatment in patients with decompensated liver disease due to HBeAg negative chronic hepatitis B. A multicenter study.

被引：0
|
作者：
Manolakopoulos, S
Karatapanis, S
Elefsiniotis, J
Goulis, J
Mathou, N
Vlachogiannakos, J
Iliadou, E
Kougioumtzan, A
Economou, M
Tzourmakliotis, D
Avgerinos, A
机构：
[1] Polyclin Gen Hosp, Athens, Greece
[2] Gen Hosp Athens Elpis, Athens, Greece
[3] Elena Venizelou Hosp, Athens, Greece
[4] Evangelismos Gen Hosp, Athens, Greece
来源：
HEPATOLOGY | 2002年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1930
引用
收藏
页码：645A / 645A
页数：1
相关论文
共 50 条
  • [1] Lamivudine treatment of advanced decompensated liver disease due to hepatitis B.
    VanThiel, DH
    Friedlander, L
    Kania, RJ
    Molloy, PJ
    Hassanein, T
    Wahlstrom, E
    Faruki, H
    GASTROENTEROLOGY, 1997, 112 (04) : A1407 - A1407
  • [2] Lamivudine treatment for decompensated cirrhosis due to hepatitis B: A multicenter longitudinal study.
    Hann, HWL
    Fontana, RJ
    Wright, T
    Baker, A
    Everson, GT
    Schiff, ER
    Riely, C
    Riker-Hopkins, M
    Hamedani, A
    Brown, NA
    GASTROENTEROLOGY, 2000, 118 (04) : A1004 - A1004
  • [3] Lamivudine treatment for patients with HBeAg negative decompensated liver disease.
    Buti, M
    Chow, WC
    Lai, MY
    Pastore, G
    Springford, H
    Hawley, S
    Simpson, KJ
    HEPATOLOGY, 2000, 32 (04) : 584A - 584A
  • [4] Response to extended lamivudine treatment of HBeAg negative chronic hepatitis B.
    Andreone, P
    Hussain, MT
    Lok, AS
    Gramenzi, A
    Cursaro, C
    Lorenzini, S
    Porzio, F
    Margotti, M
    HEPATOLOGY, 2001, 34 (04) : 321A - 321A
  • [5] Lamivudine improves liver function in patients with decompensated cirrhosis resulting from HBeAg negative HBV DNA positive chronic hepatitis B.
    Manolakopoulos, S
    Kougioumtzan, A
    Iliadou, E
    Triantos, C
    Papanikolaou, C
    Tzourmakliotis, D
    Avgerinos, A
    HEPATOLOGY, 2000, 32 (04) : 584A - 584A
  • [6] Lamivudine treatment of advanced and decompensated liver disease due to hepatitis B
    VanThiel, DH
    Friedlander, L
    Kania, RJ
    Molloy, PJ
    Hassanein, T
    Wahlstrom, E
    Faruki, H
    HEPATO-GASTROENTEROLOGY, 1997, 44 (15) : 808 - 812
  • [7] Genotypic and phenotypic resistance to lamivudine in patients with HBeAg negative chronic hepatitis B.
    Hussain, MT
    Carmela, C
    Gramenzi, A
    Fiorino, S
    Margotti, M
    Talarico, S
    Bernardi, M
    Andreone, P
    Lok, AS
    HEPATOLOGY, 2001, 34 (04) : 325A - 325A
  • [8] Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B
    Nikolaidis, N
    Vassiliadis, T
    Giouleme, O
    Tziomalos, K
    Grammatikos, N
    Patsiaoura, K
    Orfanou-Koumerkeridou, E
    Balaska, A
    Eugenidis, N
    CLINICAL TRANSPLANTATION, 2005, 19 (03) : 321 - 326
  • [9] Clinical & histological outcome of extended lamivudine in patients with HBeAg negative chronic hepatitis B.
    Esteban, R
    Goldin, RD
    Tassopoulos, NC
    Rizzetto, M
    Santantonio, T
    Heathcote, J
    Woessner, M
    Taak, NK
    HEPATOLOGY, 2001, 34 (04) : 446A - 446A
  • [10] Adefovir alone or combination with lamivudine in patients with lamivudine-resistance chronic HBeAg-negative hepatitis B. A non randomized multicenter controlled study
    Manolakopoulos, S
    Bethanis, S
    Koutsounas, S
    Goulis, J
    Saveriadis, A
    Xristias, E
    Christidou, A
    Pavlidis, C
    Toubanakis, C
    Vlachogiannakos, J
    Triantos, C
    Avgerinos, A
    Tzourmakliotis, D
    HEPATOLOGY, 2005, 42 (04) : 592A - 593A
12345